Sermorelin

Sermorelin reproduces the first 29 amino acids of human growth-hormone-releasing hormone. Instead of supplying growth hormone from outside, it tells the pituitary to make and release your own — which leaves the hypothalamic-pituitary feedback loop that normally restrains the system fully intact.

It was once sold as Geref, approved for diagnosing and treating growth hormone deficiency in children. The manufacturer withdrew that product in the early 2000s for commercial reasons, not safety ones [1]. What exists now is compounded: dispensed by licensed pharmacies on a prescription, with no branded product behind it.

Adult-wellness practitioners have taken an interest in it for supporting the GH axis as it declines with age, sometimes called somatopause. The evidence is far stronger for the childhood indication than for that use, and no large, long-term, placebo-controlled trial in healthy older adults has ever been published — a gap worth holding onto while reading any marketing about it.

It binds GHRH receptors on the somatotroph cells of the anterior pituitary, switches on cAMP signaling, and prompts growth hormone to be made and released in pulses. Because somatostatin still inhibits the pituitary normally, feedback control over GH stays in place — which is the physiologic difference from injecting growth hormone directly [6]. Its half-life after a subcutaneous injection is short, around 10 to 12 minutes, so the stimulation it produces is a pulse rather than a plateau.

The GH released then drives the liver to produce IGF-1, and IGF-1 mediates most of the tissue-building, fat-releasing and repair effects attributed to growth hormone. Since the whole chain starts at the pituitary, anyone whose pituitary is significantly damaged — after radiation, for instance — may respond weakly or not at all [5].

The clearest evidence is in children with growth hormone deficiency. A multicenter trial found that once-daily subcutaneous GHRH(1-29) significantly accelerated growth velocity through the first year of treatment [2]. A separate study reported sustained increases in growth velocity in children with idiopathic short stature [3]. Reviewing the literature comprehensively, one paper concluded it worked as an alternative to recombinant growth hormone for idiopathic childhood deficiency, with comparable tolerability [1].

In adults the picture is thinner and leans on inference. In older men and women, a controlled study of a closely related analog found GH secretion enhanced and body composition trending favorably against baseline — though the trial was small and the analog was not identical to standard sermorelin, which limits how far the result travels [4]. Another study reported GHRH treatment partially restoring GH secretion where radiation therapy had damaged the axis [7].

A further study found the GH response to low-dose GHRH(1-29) markedly blunted in patients with longstanding post-irradiation insufficiency, which reinforces the central limitation: some pituitary reserve has to remain for any of this to work [5]. And on the claims that sell it — lean mass, fat mass, sleep, libido in healthy aging adults — not one randomized human trial has ever put any of them at the center of its design. Those are extrapolations from what growth hormone does, not findings about this peptide.

Compounding prescribers typically use 200 to 500 mcg injected subcutaneously once a day, usually at bedtime so it lands with the body's own overnight GH pulse. Some protocols split it between morning and night. Injection is regarded as more reliably absorbed than an oral troche, though both get sold [6].

IGF-1 is normally measured at baseline and then every three to six months, to confirm anything biological is happening and to steer the dose. Since no approved adult regimen exists, protocols differ from prescriber to prescriber — which is worth knowing before treating any particular one as standard. Three to six months is the usual minimum before judging changes in body composition.

Being compounded, it falls outside the manufacturing oversight that applies to approved drug products, so sterility, potency and purity vary between pharmacies. Reported side effects are mostly minor and local: redness or swelling where injected, flushing, headache [1]. And because everything depends on the pituitary responding, it will not raise GH at all in someone with significant hypopituitary damage.

Keeping somatostatin feedback intact should in theory limit the risk of pathological GH excess compared with injecting growth hormone — but that theoretical advantage has never been tested head to head in a controlled trial, and it should not be quoted as though it had. It should not be used by anyone with active or previous malignancy, since the GH and IGF-1 axis promotes growth. Anyone otherwise healthy who takes it is taking it off-label.